Deals

Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”

Japanese originator Takeda has agreed to settle two-year-old anticompetitive claims lodged by wholesalers in the US that it conspired with several generics manufacturers to maintain supracompetitive pricing for its Colcrys branded treatment for gout.

European biosimilars specialist mAbxience will hand several of its biosimilars over to the global commercialization expertise of Abbott under a new agreement signed between the firms.

The FTC’s proposed consent order allowing Amgen to move ahead with its mammoth takeover of Horizon includes an interesting stipulation for industry – one involving biosimilars.

With Biogen having put its biosimilars interests on the market, multiple bidders appear to be interested in the business. Dr Reddy’s has become the latest firm to be named in media reports as vying for a deal.

Self-labelled ‘disruptor’ Mark Cuban has brought on board yet another high-demand prescription drug, following a recent deal for biosimilar Humira.

Reports have named Intas as another possible buyer for Biogen’s biosimilars business, following earlier rumors that Samsung Bioepis could be interested in a deal. Generics Bulletin spoke to both Intas and Biogen for their reaction.

As Biocon Biologics completes its integration of the biosimilars front-end business that it acquired from former partner Viatris, Biocon founder and chairperson Kiran Mazumdar-Shaw talks to Generics Bulletin about how the firm is now capturing the full value of its biosimilars, while also looking at expanding into new markets previously unserved by Viatris.

Sandoz has filled a gap in its biosimilars pipeline by in-licensing Samsung Bioepis’ SB17 ustekinumab biosimilar to Stelara, for commercialization in multiple global markets.

After PEs, Torrent Pharma is speculated to be in the fray for a stake in Cipla. Experts weigh in on the contours of the product and cultural alignment of the two firms, should things move forward and also whether other Indian players could take a shot at the 'once in a lifetime opportunity'.

Biocon Biologics has announced the latest milestone in its integration of former partner Viatris’s biosimilars business, completing the move in the US and Canada “ahead of schedule.”

Teva potentially was only a matter of days away from hearing a decision in its patent litigation battle over Vivitrol (naltrexone) long-acting injectable, but has instead put pen to paper on a settlement deal.

With around a month to go until Sandoz is expected to become a standalone company following its spinoff from parent Novartis, the firm has published additional financial information ahead of a shareholders meeting in mid-September.

Just three years after its first, Mallinckrodt has entered into another restructuring support agreement with its debt holders and opioids trust, which will be facilitated by Chapter 11 bankruptcy proceedings in the US.

Just weeks before Sandoz completes its separation from parent firm Novartis, the company has completed a deal for worldwide rights to the Mycamine antifungal brand from Astellas.

CVS feels its newly launched, wholly owned US biosimilars subsidiary called Cordavis is a “logical evolution for us and will help ensure sufficient supply of biosimilars in the US and support this market now and in the future.”